MAZE THERAPEUTICS’ Insider Trading Plan: CEO and EVP Execute Rule‑10b5‑1 Buy‑Sell Sequence, Maintaining Control While Boosting Liquidity

Insider Activity Highlights a Shift in Ownership Dynamics

On July 1 2026, President of Research & Development and Chief Marketing Officer Harold Bernstein executed a Rule 10b5‑1 buy of 14,609 shares at $10.42, followed by the sale of 14,409 shares for an average of $29.87–$30.34. The trades, all part of a pre‑established trading plan adopted on September 29, 2025, underscore a routine adjustment rather than a sudden divestiture. The net effect leaves Bernstein holding no long‑term position in the company, a departure from his historically sizable stake.

Implications for Investors and the Company’s Outlook

Bernstein’s recent pattern—alternating buys at the low end of the price spectrum with sales near the mid‑$30 range—signals a disciplined, plan‑based approach to liquidity management. While the sales reduce the immediate concentration of insider ownership, they do not materially alter the balance of power; the CEO and other officers continue to hold substantial positions. For investors, the trades may reinforce confidence that senior management is adhering to compliant, forward‑planned transactions rather than reacting to market volatility. The company’s robust 52‑week high of $53.65 and a 157.9% year‑to‑date gain suggest that the market remains bullish, and insider activity is unlikely to derail growth trajectories.

Bernstein Harold: A Profile of Structured Trading

Bernstein’s insider history is marked by a series of Rule 10b5‑1 purchases at $10.42 interspersed with option‑exercise sales in the $25–$30 range. In the past month alone, he bought 15,000 shares in mid‑May and 14,800 shares in early June, then sold approximately 46,900 shares of exercised options on July 1. This cadence—buy low, sell high—reflects a strategy aimed at capital preservation and liquidity. His option exercises, consistently executed near the current market price, demonstrate confidence in the company’s valuation while also providing a predictable cash flow stream for personal diversification.

Broader Insider Activity: A Snapshot

Beyond Bernstein, CEO Jason Coloma’s July sales and officer Atul Dandekar’s June buy/sell pair illustrate a broader trend of active equity participation among executives. While the volume of shares traded by each officer remains modest relative to the company’s market cap, the pattern of rule‑based trades points to a culture of disciplined ownership management. For investors, this reduces the risk of sudden, large‑scale insider sell‑offs that could depress the share price.

Bottom Line

Harold Bernstein’s latest transactions are part of a systematic, rule‑compliant trading plan that balances liquidity needs with long‑term equity exposure. The broader insider landscape—characterized by disciplined buying and selling—offers investors reassurance that senior leadership is managing its holdings responsibly. With the company’s fundamentals strong and the market sentiment largely neutral (social media buzz at 0 % and sentiment at –0), these insider activities are unlikely to shift the trajectory of MAZE THERAPEUTICS’ share performance in the near term.